The interventional cardiology devices market is expected to register a CAGR of nearly 6.8% during the forecast period. The major factors for the growth of the interventional cardiology devices market include the growing prevalence of coronary artery diseases (CADs), technological advancements in interventional cardiology devices, and rising demand for minimally invasive treatment.

Heart-related diseases are the most serious health conditions and are the leading cause of death, worldwide. Coronary artery disease (CAD) is one of the most common causes of morbidity and mortality in both low-income/middle-income and developed countries. The prevalence of coronary artery disease (CAD) increased in the last three decades in the low- and middle-income countries, including India. The burden of CAD increased, due to a higher prevalence of risk factors related to the changing lifestyle. As per the data of England and Wales, Office for National Statistics Deaths, in 2017, around 66,431 people died due to coronary heart disease in the United Kingdom.

The people suffering from cardiovascular diseases or those who are at high cardiovascular risk need early detection and management. Hence, most of them opt for cardiac surgeries, which in turn, helps driving the growth of the market. Therefore, the increasing burden of cardiovascular diseases, including coronary artery diseases, is anticipated to boost the usage of coronary stents and drive the market studied.

Key Market Trends

Drug-eluting Stents Segment is Expected to Dominate the Market

Drug-eluting stents are coated with medication, which is slowly released to prevent the growth of scar tissue in the artery lining. This helps the arteries to remain smooth and open, thus, ensuring good blood flow. Drug-eluting stents are usually used for lower extremities. They provide results that are better than the self-expanding and balloon-expanding stents. A good number of patients suffering from heart problems have been successfully treated with drug-eluting stents, preventing the need for more invasive procedures, such as coronary artery bypass surgery. Drug-eluting stents help in preventing the recurrence of symptoms, such as chest pain. This also reduces the need for repetitive angioplasty procedures, which carry the risk of complications, such as heart attack and stroke.

North America is Expected to Dominate the Interventional Cardiology Devices Market

The presence of sophisticated healthcare infrastructure, favorable government initiatives pertaining to product development, and high patient awareness levels, coupled with relatively high healthcare expenditures in the region, are some prominent drivers. The United States, currently, is expected to continue with its largest share in the coronary stents market. Much of the demand for and production of interventional cardiology devices are taken up by North America and Europe. North America has a high consumption rate of premium-priced interventional cardiology devices, and it is the region that can cater to a high rate of innovation in medical devices, thus, dominating this market. However, problems related to varying rates of degradation and uneven drug release have delayed the introduction of the bioabsorbable stents in the market. As a result, the US Food and Drug Administration (FDA) needs extensive animal and human study data before considering the approval of this type of technology.

Competitive Landscape

The market studied is consolidated, owing to the presence of a few major market players. The entry barriers are high in this market. Some of the market players are Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Ltd, Biotronik, Boston Scientific, Cardinal Health, Cook Medical Inc., Medtronic Inc., and Terumo Medical Corporation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support